Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087607 · ClinicalTrials.gov registry record · Phase 4
Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 385
- Enrollment target
NCT00087607 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 385 participants.
The verdict
NCT00087607, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 385 participants
- Enrollment target
Study Summary
This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Interventions
- DRUG Ribavirin
- DRUG Peginterferon alfa-2a [Pegasys]
- DRUG Peginterferon alfa-2b (PEG-Intron)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087607
The ClinicalTrials.gov registry entry for NCT00087607 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT00087607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087607 about?
NCT00087607 is a clinical study titled "Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).". This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
What is the current status of trial NCT00087607?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 385 participants. The study started on 2004-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00087607?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon alfa-2a [Pegasys] (DRUG), Peginterferon alfa-2b (PEG-Intron) (DRUG).
Who is sponsoring clinical trial NCT00087607?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.